Sökning: onr:"swepub:oai:DiVA.org:uu-446200" > Impact of Pretransp...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 09211naa a2200805 4500 | |
001 | oai:DiVA.org:uu-446200 | |
003 | SwePub | |
008 | 210622s2021 | |||||||||||000 ||eng| | |
009 | oai:prod.swepub.kib.ki.se:146688477 | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4462002 URI |
024 | 7 | a https://doi.org/10.1016/j.jtct.2021.02.0302 DOI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1466884772 URI |
040 | a (SwePub)uud (SwePub)ki | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Farhadfar, Noshau Univ Florida, Coll Med, Div Hematol Oncol, Gainesville, FL USA.4 aut |
245 | 1 0 | a Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation |
264 | 1 | b Elsevier,c 2021 |
338 | a print2 rdacarrier | |
520 | a Renal dysfunction is a recognized risk factor for mortality after allogeneic hematopoietic cell transplantation (alloHCT), yet our understanding of the effect of different levels of renal dysfunction at time of transplantation on outcomes remains limited. This study explores the impact of different degrees of renal dysfunction on HCT outcomes and examines whether the utilization of incremental degrees of renal dysfunction based on estimated glomerular filtration rate (eGFR) improve the predictability of the hematopoietic cell transplantation comorbidity index (HCT-CI). The study population included 2 cohorts: cohort 1, comprising patients age >= 40 years who under went alloHCT for treatment of hematologic malignancies between 2008 and 2016 (n = 13,505; cohort selected given a very low incidence of renal dysfunction in individuals age <40 years), and cohort 2, comprising patients on dialysis at the time of HCT (n = 46). eGFR was measured using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) method. The patients in cohort 1 were assigned into 4 categories-eGFR >= 90 mL/min (n = 7062), eGFR 60 to 89 mL/min (n = 5264), eGFR 45 to 59 mL/min (n = 897), and eGFR <45 mL/min (n=282)-to assess the impact of degree of renal dysfunction on transplantation outcomes. Transplantation outcomes in patients on dialysis at the time of alloHCT were analyzed separately. eGFR <60 mL/min was associated with an increased risk for nonrelapse mortality (NRM) and requirement for dialysis post-HCT. Compared with the eGFR >= 90 group, the hazard ratio (HR) for NRM was 1.46 (P = .0001) for the eGFR 45 to 59 mL/min group and 1.74 (P = .004) for the eGFR <45 mL/min group. Compared with the eGFR >= 90 mL/min group, the eGFR 45 to 59 mL/min group (HR, 2.45; P < .0001) and the eGFR <45 mL/min group (HR, 3.09; P < .0001) had a higher risk of renal failure necessitating dialysis after alloHCT. In addition, eGFR <45 mL/min was associated with an increased overall mortality (HR, 1.63; P < .0001). An eGFR-based revised HCT-CI was also developed and shown to be predictive of overall survival (OS) and NRM, with predictive performance similar to the original HCT-CI. Among 46 patients on dialysis at alloHCT, the 1-year probability of OS was 20%, and that of NRM was 67%. The degree of pretransplantation renal dysfunction is an independent predictor of OS, NRM, and probability of needing dialysis after alloHCT. An eGFR-based HCT-CI is a validated index for predicting outcomes in adults with hematologic malignancies undergoing alloHCT. The outcomes of alloHCT recipients on dialysis are dismal; therefore, one should strongly weigh the significant risks of being on hemodialysis as a factor in determining alloHCT candidacy. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Urologi och njurmedicin0 (SwePub)302142 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Urology and Nephrology0 (SwePub)302142 hsv//eng |
653 | a Renal dysfunction | |
653 | a HCT-CI | |
653 | a Allogeneic transplantation | |
653 | a Dialysis | |
700 | 1 | a Dias, Ajoyu Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.4 aut |
700 | 1 | a Wang, Taou Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA.;Med Coll Wisconsin, Inst Hlth & Equ, Div Biostat, Milwaukee, WI 53226 USA.4 aut |
700 | 1 | a Fretham, Caitrinu Natl Marrow Donor Program Be Match, CIBMTR Ctr Int Blood & Marrow Transplant Res, Minneapolis, MN USA.4 aut |
700 | 1 | a Chhabra, Saurabhu Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA.;Med Coll Wisconsin, Dept Med, Div Hematol Oncol, Milwaukee, WI 53226 USA.4 aut |
700 | 1 | a Murthy, Hemant S.u Mayo Clin, Div Hematol Oncol, Blood & Marrow Transplantat Program, Jacksonville, FL USA.4 aut |
700 | 1 | a Broglie, Larisau Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA.;Childrens Hosp Wisconsin, Milwaukee, WI 53201 USA.4 aut |
700 | 1 | a D'Souza, Anitau Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA.4 aut |
700 | 1 | a Gadalla, Shahinaz M.u NCI, Div Canc Epidemiol & Genet, NIH, Clin Genet Branch, Rockville, MD USA.4 aut |
700 | 1 | a Gale, Robert Peteru Imperial Coll London, Haematol Res Ctr, Dept Immunol & Inflammat, London, England.4 aut |
700 | 1 | a Hashmi, Shahrukhu Mayo Clin, Dept Internal Med, Rochester, MN USA.;Sheikh Shakhbout Med City, Dept Med, Abu Dhabi, U Arab Emirates.4 aut |
700 | 1 | a Al-Homsi, A. Sameru New York Univ Langone Hlth, New York, NY USA.4 aut |
700 | 1 | a Hildebrandt, Gerhard C.u Univ Kentucky, Markey Canc Ctr, Lexington, KY USA.4 aut |
700 | 1 | a Hematti, Peimanu Univ Wisconsin, Dept Med, Div Hematol Oncol Bone Marrow Transplantat, Madison, WI USA.4 aut |
700 | 1 | a Rizzieri, Davidu Duke Univ, Div Hematol Malignancies & Cellular Therapy, Durham, NC USA.4 aut |
700 | 1 | a Chee, Lynetteu Royal Melbourne Hosp City Campus, Parkville, Vic, Australia.;Peter MacCallum Canc Ctr, Parkville, Vic, Australia.4 aut |
700 | 1 | a Lazarus, Hillard M.u Case Western Reserve Univ, Univ Hosp Cleveland Med Ctr, Cleveland, OH 44106 USA.4 aut |
700 | 1 | a Bredeson, Christopheru Ottawa Hosp, Blood & Marrow Transplant Program, Ottawa, ON, Canada.;Ottawa Hosp Res Inst, Ottawa, ON, Canada.4 aut |
700 | 1 | a Jaimes, Edgar A.u Mem Sloan Kettering Canc Ctr, Renal Serv, 1275 York Ave, New York, NY 10021 USA.4 aut |
700 | 1 | a Beitinjaneh, Ameru Univ Miami, Div Transplantat & Cellular Therapy, Miami, FL USA.4 aut |
700 | 1 | a Bashey, Asadu Northside Hosp, Blood & Marrow Transplant Program, Atlanta, GA USA.4 aut |
700 | 1 | a Prestidge, Timu Starship Childrens Hosp, Blood & Canc Ctr, Auckland, New Zealand.4 aut |
700 | 1 | a Krem, Maxwell M.u Univ Kentucky, Coll Med, Markey Canc Ctr, Lexington, KY USA.4 aut |
700 | 1 | a Marks, David, Iu Univ Hosp Bristol NHS Trust, Adult Bone Marrow Transplant, Bristol, Avon, England.4 aut |
700 | 1 | a Benoit, Stefanieu Cincinnati Childrens Hosp Med Ctr, Div Nephrol & Hypertens, Cincinnati, OH 45229 USA.;Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA.4 aut |
700 | 1 | a Yared, Jean A.u Univ Maryland, Dept Med, Greenebaum Comprehens Canc Ctr, Blood & Marrow Transplantat Program,Div Hematol O, Baltimore, MD 21201 USA.4 aut |
700 | 1 | a Nishihori, Taigau H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplant & Cellular Immunot, Tampa, FL USA.4 aut |
700 | 1 | a Olsson, Richard F.u Uppsala universitet,Centrum för klinisk forskning i Sörmland (CKFD),Karolinska Inst, Dept Lab Med, Stockholm, Sweden4 aut0 (Swepub:uu)riols677 |
700 | 1 | a Freytes, Cesar O.u Texas Transplant Inst, San Antonio, TX USA.4 aut |
700 | 1 | a Stadtmauer, Edwardu Univ Penn, Med Ctr, Abramson Canc Ctr, Philadelphia, PA 19104 USA.4 aut |
700 | 1 | a Savani, Bipin N.u Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol Oncol, Nashville, TN USA.4 aut |
700 | 1 | a Sorror, Mohamed L.u Fred Hutchinson Canc Res Ctr, Clin Res Div, Washington, DC USA.;Univ Washington, Sch Med, Dept Med, Div Med Oncol, Seattle, WA 98195 USA.4 aut |
700 | 1 | a Ganguly, Siddharthau Univ Kansas Hlth Syst, Div Hematol Malignancy & Cellular Therapeut, Kansas City, KS USA.4 aut |
700 | 1 | a Wingard, John R.u Univ Florida, Dept Med, Div Hematol & Oncol, Gainesville, FL USA.4 aut |
700 | 1 | a Pasquini, Marcelou Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA.4 aut |
710 | 2 | a Univ Florida, Coll Med, Div Hematol Oncol, Gainesville, FL USA.b Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.4 org |
773 | 0 | t Transplantation and Cellular Therapyd : Elsevierg 27:5, s. 410-422q 27:5<410-422x 2666-6375x 2666-6367 |
856 | 4 | u https://doi.org/10.1016/j.jtct.2021.02.030 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-446200 |
856 | 4 8 | u https://doi.org/10.1016/j.jtct.2021.02.030 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:146688477 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy